NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Jdheart, this checkpoint inhibitor (jempeli, dostarlimab) does not cure all cancers. However, it is very effective in cancer patients having tumors with a specific genetic makeup which is known as "mismatch repair deficient (MMRd) or Microsatellite Instability (MSI).

Only about 10% of the patients with colorectal cancer have this type of tumor and
can therefore be cured with this checkpoint inhibitor.

I am not underestimating this piece of good news. Any treatment that reduces cancer related mortalities and morbidities is a big plus.